Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Uterine Cervical Neoplasms 8Squamous Cell Carcinoma of Head and Neck 5Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Neuroblastoma 3Medulloblastoma 3Ganglioneuroblastoma 3Gallbladder Neoplasms 3Cholangiocarcinoma 3Urethral Neoplasms 2Ureteral Neoplasms 2Pancreatic Neoplasms 2Oropharyngeal Neoplasms 2Brenner Tumor 2Vulvar Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 1Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 1Sarcoma 1Rhabdoid Tumor 1Recurrent Uterine Corpus Carcinoma 1Recurrence 1Prostatic Neoplasms 1Pinealoma 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroendocrine Tumors 1

Interventions

Ipilimumab 114pembrolizumab 95Nivolumab 91aldesleukin 86Interleukin-2 57Cyclophosphamide 54Dacarbazine 52Vemurafenib 39trametinib 37Temozolomide 37incomplete Freund's adjuvant 35fludarabine phosphate 35sargramostim 32dabrafenib 32fludarabine 26Bevacizumab 26Paclitaxel 22MART-1 Antigen 21Granulocyte-Macrophage Colony-Stimulating Factor 21montanide ISA 51 20Interferon-alpha 20Cisplatin 20Carboplatin 19Sorafenib 18Introns 17Biopsy 17cobimetinib 16Radiosurgery 16atezolizumab 15Radiotherapy 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Melanoma × 1,2-diaminocyclohexaneplatinum II citrate × Clear all
NCT01196416 2019-11-18

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma

National Cancer Institute (NCI)

Phase 1/2 Completed
14 enrolled 16 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡